A contemporary update on rates and management of toxicities of targeted therapies for metastatic renal cell carcinoma-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

A contemporary update on rates and management of toxicities of targeted therapies for metastatic renal cell carcinoma

Published:2013-06 Issue:4 Volume:39 Page:388-401
ISSN:0305-7372
Container-title:Cancer Treatment Reviews
language:en
Short-container-title:Cancer Treatment Reviews

Author:

Alasker Ahmed,Meskawi Malek,Sun Maxine,Ismail Salima,Hanna Nawar,Hansen Jens,Tian Zhe,Bianchi Marco,Perrotte Paul,Karakiewicz Pierre I.

Funder

Fonds de la Recherche en Santé du Québec

University of Montreal, Department of Surgery

University of Montreal Health Centre (CHUM) Foundation

Publisher

Elsevier BV

Subject

Radiology, Nuclear Medicine and imaging,Oncology,General Medicine

Reference139 articles.

1. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma;Motzer;J Clin Oncol,2009

2. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma;Motzer;N Engl J Med,2007

3. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial;Sternberg;J Clin Oncol,2010

4. Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival;Escudier;J Clin Oncol,2010

5. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial;Escudier;Lancet,2007

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Renal toxicity of targeted therapies for renal cell carcinoma in patients with normal and impaired kidney function;Cancer Chemotherapy and Pharmacology;2021-03-25

2. Thoracic Manifestations of Genitourinary Neoplasms and Treatment-related Complications;Journal of Thoracic Imaging;2019-05

3. Pazopanib: Evidence review and clinical practice in the management of advanced renal cell carcinoma;BMC Pharmacology and Toxicology;2018-11-26

4. Implementation of a Nurse-driven Educational Program Improves Management of Sorafenib’s Toxicities in Hepatocellular Carcinoma;Cancer Nursing;2018-09

5. Recent Advances in the Development of Indazole‐based Anticancer Agents;ChemMedChem;2018-06-26

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3